Deals and Financings
• China Resources Holdings will join with Bangkok's Charoen Pokphand Group to launch a $300 million life science fund, based in Hong Kong;
• Indivior of the UK out-licensed China rights for its opioid addiction tablet to Zhejiang Pukang Biotech in a $122.5 million deal;
• DNAnexus, a California biomedical informatics and DNA data management company, closed a $68 million round from investors including WuXi NextCODE;
• HiberCell, a New York City biotech startup, raised $60.75 million in Series A funding, with China investors Hillhouse and 6 Dimensions participating;
• Bolt Biotherapeutics of San Francisco completed a $54 million Series B financing led by Hong Kong's Pivotal bioVenture Partners/Nan Fung Life Sciences;
• EdiGene, a Beijing-Cambridge, MA gene editing company, completed a $10 Million Series pre-B Plus, led by Shenzhen Green Pine Capital Partners;
• Shanghai's MicuRx acquired China rights to an investigational treatment for antibiotic-resistant infections from Recida Therapeutics of the US;
• Suzhou GeneQuantum Healthcare formed a collaboration with MITRO Biotech of Nanjing to develop next-gen radionuclide conjugates;
Trials and Approvals
• Suzhou Innovent Biologics (HK: 01801) was granted NMPA approval to start trials of a PD-1 bi-specific drug for hematological and advanced solid tumors;
• CStone Pharma of Suzhou and Nanjing's Impact Therapeutics filed to start trials of a dual drug therapy that combines CStone's PD-L1 mAb with Impact's PARP inhibitor.
Disclosure: none.
Share this with colleagues: